Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more
Nanhua Bio Medicine Co Ltd (000504) - Total Assets
Latest total assets as of September 2025: CN¥841.96 Million CNY
Based on the latest financial reports, Nanhua Bio Medicine Co Ltd (000504) holds total assets worth CN¥841.96 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nanhua Bio Medicine Co Ltd - Total Assets Trend (1989–2024)
This chart illustrates how Nanhua Bio Medicine Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nanhua Bio Medicine Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanhua Bio Medicine Co Ltd's total assets of CN¥841.96 Million consist of 66.1% current assets and 33.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 34.1% |
| Accounts Receivable | CN¥143.98 Million | 23.7% |
| Inventory | CN¥34.06 Million | 5.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.86 Million | 0.3% |
| Goodwill | CN¥1.98 Million | 0.3% |
Asset Composition Trend (1989–2024)
This chart illustrates how Nanhua Bio Medicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanhua Bio Medicine Co Ltd's current assets represent 66.1% of total assets in 2024, an increase from 29.8% in 1989.
- Cash Position: Cash and equivalents constituted 34.1% of total assets in 2024, up from 4.4% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1989.
- Asset Diversification: The largest asset category is accounts receivable at 23.7% of total assets.
Nanhua Bio Medicine Co Ltd Competitors by Total Assets
Key competitors of Nanhua Bio Medicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Nanhua Bio Medicine Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nanhua Bio Medicine Co Ltd generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nanhua Bio Medicine Co Ltd is currently not profitable relative to its asset base.
Nanhua Bio Medicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.83 | 1.15 |
| Quick Ratio | 1.29 | 1.76 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥153.08 Million | CN¥ 223.77 Million | CN¥ 61.44 Million |
Nanhua Bio Medicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanhua Bio Medicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.92 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | CN¥608.17 Million |
| Market Capitalization | $288.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanhua Bio Medicine Co Ltd's assets below their book value (0.47 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nanhua Bio Medicine Co Ltd's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanhua Bio Medicine Co Ltd (1989–2024)
The table below shows the annual total assets of Nanhua Bio Medicine Co Ltd from 1989 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥608.17 Million | -21.16% |
| 2023-12-31 | CN¥771.38 Million | +39.47% |
| 2022-12-31 | CN¥553.06 Million | -16.11% |
| 2021-12-31 | CN¥659.25 Million | +18.54% |
| 2020-12-31 | CN¥556.14 Million | +107.26% |
| 2019-12-31 | CN¥268.33 Million | -21.70% |
| 2018-12-31 | CN¥342.71 Million | -15.33% |
| 2017-12-31 | CN¥404.78 Million | +34.39% |
| 2016-12-31 | CN¥301.19 Million | +145.35% |
| 2015-12-31 | CN¥122.76 Million | +15.12% |
| 2014-12-31 | CN¥106.63 Million | -15.30% |
| 2013-12-31 | CN¥125.89 Million | +65.52% |
| 2012-12-31 | CN¥76.06 Million | -72.49% |
| 2011-12-31 | CN¥276.47 Million | -3.61% |
| 2010-12-31 | CN¥286.82 Million | -30.42% |
| 2009-12-31 | CN¥412.24 Million | -23.16% |
| 2008-12-31 | CN¥536.52 Million | -21.25% |
| 2007-12-31 | CN¥681.31 Million | +6.88% |
| 2006-12-31 | CN¥637.48 Million | -1.63% |
| 2005-12-31 | CN¥648.02 Million | +7.31% |
| 2004-12-31 | CN¥603.88 Million | +1.37% |
| 2003-12-31 | CN¥595.75 Million | -3.92% |
| 2002-12-31 | CN¥620.07 Million | +3.18% |
| 2001-12-31 | CN¥600.98 Million | +0.66% |
| 2000-12-31 | CN¥597.05 Million | +24.52% |
| 1999-12-31 | CN¥479.49 Million | -24.02% |
| 1998-12-31 | CN¥631.05 Million | -15.17% |
| 1997-12-31 | CN¥743.86 Million | -3.01% |
| 1996-12-31 | CN¥766.94 Million | -10.93% |
| 1995-12-31 | CN¥861.03 Million | +3.60% |
| 1994-12-31 | CN¥831.10 Million | +6.23% |
| 1993-12-31 | CN¥782.34 Million | +71.85% |
| 1992-12-31 | CN¥455.24 Million | +103.77% |
| 1991-12-31 | CN¥223.41 Million | +168.59% |
| 1990-12-31 | CN¥83.18 Million | +337.63% |
| 1989-12-31 | CN¥19.01 Million | -- |